Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

New approaches to treating lung cancer patients in New Mexico

This year, more than 158,000 Americans are expected to die from lung cancer. That's a staggering number: it's more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined.

26 Oct 2015

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.

23 Oct 2015

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

23 Oct 2015

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

An international research team led by scientists at the University of New Mexico Cancer Center discovered and developed a novel ligand peptide-mimic that inhibits abnormal overgrowth of blood vessels in retinal diseases and tumors. The discovery could lead to new drugs that keep cancers from growing. The team published a paper in the journal Science Translational Medicine.

15 Oct 2015

Clinical study results of VolitionRx's NuQ test for pancreatic cancer published in Clinical Epigenetics

VolitionRx Limited today announced that full results from a completed clinical study of its NuQ blood-based test for early stage pancreatic cancers have been published in the online issue of Clinical Epigenetics, the official journal of the Clinical Epigenetics Society.

14 Oct 2015

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

The US Food and Drug Administration has approved SonaCare Medical's Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables treatment of organ-confined prostate disease while preserving surrounding healthy tissue, without radiation or surgery.

14 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.

8 Oct 2015

New book suggests ways to reduce medical reversals

Medical reversal—when accepted medical interventions are abandoned because they are found to be ineffective—is the "most important problem in medicine today," according to the authors of a new book: Ending Medical Reversal.

8 Oct 2015

UT Southwestern investigators develop new strategy to classify cancers caused by KRAS mutations

UT Southwestern Medical Center researchers have developed a classification for cancers caused by KRAS, the most frequently mutated gene in cancer, that could eventually help oncologists choose more effective, customized cancer therapies.

8 Oct 2015

Invitae announces dramatic expansion of genetic testing menu

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin releasing the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric and other rare disorders.

7 Oct 2015

TUM, Stanford University scientists create new cancer therapy concept

Pancreatic cancer is one of the most aggressive forms of cancer and one of the most difficult to treat. Its high resistance to treatment is a major problem, particularly in the advanced stages.

24 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Drug combination delivers effective punch against one form of pancreatic cancer

One form of pancreatic cancer has a new enemy: a two-drug combination discovered by UF Health researchers that inhibits tumors and kills cancer cells in mouse models.

22 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today reported positive data from the completed Phase 1 multiple ascending dose, placebo controlled clinical trial of BNC210, an orally administered negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (alpha-7 receptor) being developed for the treatment of anxiety and depression.

16 Sep 2015

US-Ireland partnership awarded £2.9m to develop nanomedicine for treatment of pancreatic cancer

A US-Ireland partnership involving researchers at Queen's University Belfast has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.

14 Sep 2015

Diabetes drug 'suffocates' pancreatic cancer stem cells, new study finds

A new study shows that pancreatic cancer stem cells (PancSCs) are virtually addicted to oxygen-based metabolism, and could be "suffocated" with a drug already used to treat diabetes.

14 Sep 2015

Innovative technologies offer hope to people living with chronic pain

More than 100 million people in this country have pain that won't go away. Many of these chronic pain sufferers fail to get relief from pills, shots and even surgery, while others temporarily trade the pain for side effects such as drowsiness or digestive problems.

11 Sep 2015

Johns Hopkins Kimmel Cancer Center to break ground on new cancer care building in East Baltimore

The Johns Hopkins Kimmel Cancer Center will break ground Sept. 10 on a new $100 million, 184,000-square-foot cancer care building at one of the highest elevations in East Baltimore.

11 Sep 2015

Pancreatic Cancer News and Research

Further Reading

New approaches to treating lung cancer patients in New Mexico

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

New combination treatment approved by FDA for metastatic pancreatic cancer

Novel ligand peptide-mimic inhibits abnormal overgrowth of blood vessels, may lead to new anti-cancer drugs

Clinical study results of VolitionRx's NuQ test for pancreatic cancer published in Clinical Epigenetics

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

New book suggests ways to reduce medical reversals

UT Southwestern investigators develop new strategy to classify cancers caused by KRAS mutations

Invitae announces dramatic expansion of genetic testing menu

TUM, Stanford University scientists create new cancer therapy concept

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Drug combination delivers effective punch against one form of pancreatic cancer

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Bionomics’ BNC210 Phase 1 trial for anxiety and depression meets primary endpoint

US-Ireland partnership awarded £2.9m to develop nanomedicine for treatment of pancreatic cancer

Diabetes drug 'suffocates' pancreatic cancer stem cells, new study finds

Innovative technologies offer hope to people living with chronic pain

Johns Hopkins Kimmel Cancer Center to break ground on new cancer care building in East Baltimore

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News